San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Just what did GlaxoSmithKline (GSK) get for its dime when, in 2008, it dropped $720 million (or 72 billion dimes) to buy Sirtris Pharmaceuticals? Pharmaceutical Preparations . Founded in 2004, Sirtris went public in May 2007 and continues as an independent discovery performance unit within GSK. Sirtris Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics that modulate sirtuins, a recently discovered family of enzymes that promotes the body's natural defense against disease. CAMBRIDGE, Mass.- Sirtris Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today publication of a study by Sirtris and Harvard University scientists … Pharmaceutical Preparations. Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. The buyout was another giant coup for Sirtris … Sirtris Pharmaceuticals Living Healthier Longer Case Study Solution & Analysis. Dr. David Sinclair is co-founder of several biotechnology companies (Sirtris Pharmaceuticals, Genocea Biosciences, OvaScience, CohBar, MetroBiotech, ArcBio, Liberty Biosecurity) and is on the boards of several others (most notably Shaklee). Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs … Sirtris Pharmaceuticals, Inc. S. Sirtris Pharmaceuticals, Inc. GlaxoSmithKline plc (NYSE: GSK) announced today the successful completion of the tender offer by its wholly-owned subsidiary Fountain Acquisition Corporation (FAC) for shares of common Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. "Sirtris Pharmaceuticals Living Healthier Longer" Essays and Research Papers . Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. [5][17][18] At that time, GSK/Sirtris' lead candidate was SRT2104, described as a "first-generation sirtuin-activating compound. Medvedik has worked as a biotechnology consultant at Sirtris Pharmaceuticals and has taught molecular and synthetic biology to hundreds of students while at Harvard University, The Cooper Union, School of Visual Arts, Genspace and NYU. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization, Auto-generated name of transaction (e.g. Global Market Direct's pharmaceuticals report, "Sirtris Pharmaceuticals, Inc. - Product Pipeline Review - 2013" provides data on the Sirtris Pharmaceuticals, Inc.'s research and development focus. The successful organizations such as Sirtris Gsk's are the one who able to predict market trends better than others, provide resources to develop products and services to leverage those trends, able to counter competitors’ threats, and meet customers’ expected value proposition. Sirtris Pharmaceuticals Team Add Team Member. Eric W Jacobson is Chief Medical Officer at Sirtris Pharmaceuticals Inc. See Eric W Jacobson's compensation, career history, education, & memberships. And that was the case when GlaxoSmithKline, the British drug company with U.S. headquarters in the Triangle, announced its $720 million purchase of Massachusetts’ Sirtris Pharmaceuticals. "Sirtris is delighted to welcome Mike, who brings to our team a wealth of experience in discovery research, particularly in the metabolic field," said Christoph Westphal, M.D., Ph.D., CEO of Sirtris Pharmaceuticals. Sirtris Pharmaceuticals develops small molecule drugs for the treatment of aging and metabolic diseases. [7][8][9][10][11][12], In August 2010, a nonprofit called the Healthy Lifespan Institute, which had been formed the year before by Westphal and Michelle Dipp, who joined GSK from Sirtris, began selling SRT501 as a dietary supplement online;[4] when this become public GSK required Westphal and Dipp, who were still GSK employees, to resign from the nonprofit. Chemical base materials; Plastic products; Chemical products; Chemical industry plant and equipment; Rubber and plastic industry plant and equipment ; Health, medical and pharmaceutical; Rubber products; Construction. As followers of the drug industry know, GlaxoSmithKline famously paid $720 million to buy Sirtris Pharmaceuticals in 2008. But Sirtris pulled it off, via M&A, when GSK tendered a whopping $720 million for it in April. Sirtris Pharmaceuticals, Inc. was founded in 2008. Chemicals, Pharmaceuticals & Plastics. WhatsApp acquired by Facebook). The company's business plan was based on … The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. Xconomy Boston — [Updated 2:25 pm ET, 3/13/13] GlaxoSmithKline is closing down Cambridge, MA-based Sirtris Pharmaceuticals, almost five … CAMBRIDGE, Mass.- Sirtris Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today publication of a study by Sirtris and Harvard University scientists in the journal Cell that reveals a new mechanism to slow aging. [1], The company was specifically focused on resveratrol formulations and derivatives as activators of the SIRT1 enzyme; Sinclair became known for making statements about resveratrol like: “(It's) as close to a miraculous molecule as you can find.... One hundred years from now, people will maybe be taking these molecules on a daily basis to prevent heart disease, stroke, and cancer.”[1] Most of the anti-aging field was more cautious, especially with regard to what else resveratrol might do in the body and its lack of bioavailability. David Sinclair Harvard Medical School Department of Pathology NRB, 9 th Floor 77 Avenue Louis Pasteur Boston, MA 02115. Sirtris Pharmaceuticals Inc Sirtris Pharmaceuticals, Inc. operates as a biopharmaceutical company. Product Status Description; There are no products. ", "SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1", "Doubt on Anti-Aging Molecule as Resveratrol Trial Is Halted", "GlaxoSmithKline Halts All Further Development Of Resveratrol Drug SRT501", "GSK absorbs controversial 'longevity' company : News blog", "GlaxoSmithKline Shuts Down Sirtris, Five Years After $720M Buyout", https://en.wikipedia.org/w/index.php?title=Sirtris_Pharmaceuticals&oldid=968238491, Biotechnology companies of the United States, Creative Commons Attribution-ShareAlike License, This page was last edited on 18 July 2020, at 03:23. PA. Collegeville. Many people from all over the world come to the United Stats to turn their Wheel of Fortune. Products; Resources; My Account; Talk to a D&B Advisor 1-800-280-0780. Business Directory. GlaxoSmithKline (NYSE: GSK) has announced that it has entered into a definitive acquisition pact with Sirtris Pharmaceuticals Inc. (NASDAQ: SIRT). New Pathway for Developing Treatments for Diseases of Aging. Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. [6], Studies published in 2009 and early 2010 by scientists from Amgen and Pfizer cast doubt on whether SIRT1 was directly activated by resveratrol and showed that the apparent activity was actually due to a fluorescent reagent used in the experiments. Multistage venture capital investors with focus Technology, Healthcare and Consumer : United States : 6630 Fund management: edit Sirtris’ focus to date has been on the development of SIRT1 activators for the treatment of Type 2 Diabetes Mellitus (T2DM). See reviews, photos, directions, phone numbers and more for Sirtris Pharmaceuticals Inc locations in Cambridge, MA. Professor Toby Stuart and Senior Researcher Discovery Reveals Critical Role of SIRT3 and SIRT4 in Cell Metabolism. GSK is one of the largest pharmaceutical companies in the world, headquartered in London; it has significant products in both consumer and pharmaceutical areas. Acquired by GSK (GlaxoSmithKline) on April 22, 2008 Founded: January 01, 2004 The Pharmaceutical Industry And Health Professional Services. We use cookies to provide you with a better experience. Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. See reviews, photos, directions, phone numbers and more for Sirtris Pharmaceuticals Inc locations in Cambridge, MA. A high-level overview of Sirtris Pharmaceuticals (SIRT) stock. By continuing to ... Use your energy where it's needed most — ensuring that your products are in compliance and … Sirtris Pharmaceuticals, Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Rare, Progressive Disorder Caused by Mutation in DNA of Mitochondria Has No Known Treatments CAMBRIDGE, MA, USA | August 9, 2007 | Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, today announced the initiation of a Phase 1b clinical trial … Advantages of Living in America. In most courses studied at Harvard Business schools, students are provided with a case study. Developer of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases. Sirtris Pharmaceuticals: Living Healthier, Longer Fortune, February 12, 2007. Dear David: Thank you for agreeing to become a consultant to Sirtris Pharmaceuticals, Inc. (the "Company"). "[18][19], "Tests Begin on Drugs That May Slow Aging", "Former Sirtris Execs' Nonprofit Starts Selling Resveratrol with Potential Anti-Aging Effects Online", "UPDATED: GSK moves to shutter Sirtris' Cambridge office, integrate R&D", "The Sirtris Compounds: Worthless? Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. 1250 S COLLEGEVILLE RD COLLEGEVILLE, PA 19426 Get Directions (585) 275-5774. Business Info. The field of sirtuins received high profile exposure last year when GlaxoSmithKline paid $720m to acquire Sirtris Pharmaceuticals, one of the few companies developing a clinical stage pipeline of products which interact with these enzymes which regulate multiple metabolic pathways. CLAIM THIS BUSINESS. Their focus to date has been on the development of SIRT1 activators for the treatment of Type 2 Diabetes Mellitus (T2DM). GlaxoSmithKline (GSK) has offered to buy all outstanding shares of Sirtris Pharmaceuticals for $22.50 a share. Sirtris Pharmaceuticals Inc. has been sold for $720 million to international pharmaceutical company GlaxoSmithKline (NYSE: GSK), just four years after the biotechnology startup launched. the FDA require that animals of both sexes be included in non-clinical studies? The firm is mulling to relocate some of the 60 staffers currently working at the site in Cambridge to Philadelphia office. GlaxoSmithKline acquires Sirtris Pharmaceuticals for approximately $720 million through a cash tender offer and merger of $22.50 per share, the firms state June 6. Sirtris has already started a larger drug study. Find 424 listings related to Sirtris Pharmaceuticals Inc in Cambridge on YP.com. See Appendix for pictures of the covers of the Wall Street Journal and Fortune. GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND CAMBRIDGE, Mass., April 22 -- Their focus to date has been on the development of SIRT1 activators for the treatment of Type 2 Diabetes Mellitus (T2DM). Get information, directions, products, services, phone numbers, and reviews on Sirtris Pharmaceuticals in Collegeville, undefined Discover more Pharmaceutical Preparations companies in Collegeville on … Sirtris Pharmaceuticals is funded by 10 investors. Living in the United States has Advantages over living in my country America- A country of Immigrants. Thomas Salzmann is Former Chairman at Satori Pharmaceuticals Inc. See Thomas Salzmann's compensation, career history, education, & memberships. Sirtris Pharmaceuticals has raised a total of $82M in funding over 4 rounds. Type 2 Diabetes (T2D) has reached epidemic proportions in the United States. Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … Consultant to the CEO Jan 2004 to Jan 2006 Kevin Bitterman. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. [5] GSK paid $22.50/share, when Sirtris's stock was trading at $12/share, down 45% from its highest price of the previous year. Sirtris Pharmaceuticals From Wikipedia, the free encyclopedia Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. SIRTRIS PHARMACEUTICALS, INC. April 15, 2005. [13][14], GSK/Sirtris terminated development of SRT501 in late 2010. Solved Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged) case study solution include SWOT Analysis, PESTEL Analysis, VRIO Analysis, Porter Five Forces Analysis & Value Chain Analysis, BCG Growth Share Analysis. Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … Pathway-oriented platforms are rare, and dealmaking around them can be complicated: partner too early or for too little and you risk giving away the store. Should the company establish a proposed alliance with a pharmaceutical firm? The research is at a very early stage and it may take years before the drug could be submitted for approval. GlaxoSmithKline (GSK) is closing its Sirtris Pharmaceuticals office in Cambridge and fully integrating its research and development (R&D) operations with Philadelphia office. Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 17, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, … Sirtris Pharmaceuticals is registered under the ticker NASDAQ:SIRT . Sirtris Pharmaceuticals, Inc. specializes in Pharmaceutical Preparations. Sirtris Pharmaceuticals develops small molecule drugs for the treatment of aging and metabolic diseases. See Appendix for pictures of the covers of the Wall Street Journal and Fortune. N9-808-112 MARCH 18, 2008 TOBY STUART DAVID KIRON Sirtris Pharmaceuticals: Living Healthier, Longer “You can live to be a hundred if you give up all the things that make you want to live to be a hundred. Sirtris Pharmaceuticals: Living Healthier, Longer by Toby Stuart , David Kiron , (No reviews yet) Write a Review [15][16] The company said at that time that it was focused on two compounds called SRT2104 and SRT2379 that were not resveratrol analogs, had better drug-like qualities, and were more selective SIRT1 activators. Then in 2013, GlaxoSmithKline shut down Sirtris Pharmaceuticals completely, but indicated that they would be following up on many of Sirtris’s other sirtuins-activating compounds (Click here to read more on this). ", "Doubts Build On Glaxo's Antiaging Drugs", "Sirtuins: Antiaging Medicines or Marketing? [4], Sirtris went public in 2007 and was subsequently purchased and made a subsidiary of GlaxoSmithKline in 2008 for $720 million. Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that GSK says has the potential to generate multiple clinically and commercially important products. Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. Their stock opened with $10.00 in its May 23, 2007 IPO. Sirtris Pharmaceuticals Products Add Product. Sirtris Pharmaceuticals Inc., a biopharmaceutical company engaged in developing small molecule drugs that target the sirtuins, a recently discovered family of seven enzymes associated with the aging process, was acquired by GlaxoSmithKline (NYSE: GSK) in June of 2008 and now operates as the company’s wholly-owned subsidiary. The deal is another example of Pharma's interest in platform biotechs and its hunger for innovation. Explore. Major HBR cases concerns on a whole industry, a whole organization or some part of organization; profitable or non-profitable organizations. Case Description of GSK's Acquisition of Sirtris: Independence or Integration? Conceived in 2004 by Harvard University biologist David Sinclair and serial entrepreneur Andrew Perlman,[1] and founded that year by Sinclair and Perlman, along with Christoph Westphal, Richard Aldrich, Richard Pops, and Paul Schimmel,[2] the company was focused on developing Sinclair's research into activators of sirtuins, work that began in the laboratory of Leonard P. Guarente where Sinclair worked as a post-doc before starting his own lab. 481 - 490 of 500 . Really? In 2008, GlaxoSmithKline (GSK) purchased Sirtris Pharmaceuticals for $720 million in order to continue to expand its portfolio of potential drugs to be commercialized in the future. And, should it in-license a second drug development candidate? [15][16], In 2013 GSK shut down Sirtris and its development candidates were absorbed into GSK, where research and development continued. Toby Stuart, James Webber focus on Innovation & Entrepreneurship and Decision making, Entrepreneurship, Growth strategy, Leadership, Risk management. Person Role Period; Brian Shin. Sirtris Pharmaceuticals acquired by GlaxoSmithKline, Name of the organization that made the acquisition, Total amount raised across all funding rounds, Total number of current team members an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Their latest funding was raised on Apr 19, 2006 from a Series C round. Sirtris Pharmaceuticals develops small molecule drugs for the treatment of aging and metabolic diseases. Professor Toby Stuart and Senior Researcher The Company discovers and develops proprietary, orally available, small molecule drugs. Should the company establish a proposed alliance with a pharmaceutical firm? As followers of the drug industry know, GlaxoSmithKline famously paid $720 million to buy Sirtris Pharmaceuticals in 2008. And Sirtris/GSK faces long years of rigorous research before this nook of the anti-aging field yields a marketed drug. London-based Glaxo said Tuesday it agreed to buy Sirtris in an all-cash tender offer at $22.50 a share. Active, Closed, Last funding round type (e.g. [1][3] The company's initial product was called SRT501, and was a formulation of reservatrol. Sirtris has generated a lot of hype because it is developing anti-aging drugs, some of which are based on resveratrol, a chemical in red wine. Sirtris Pharmaceuticals: Living Healthier, Longer Fortune, February 12, 2007. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Their focus to date has been on the development of SIRT1 activators for the treatment of Type 2 Diabetes Mellitus (T2DM). Sirtris Pharmaceuticals: Living Healthier, Longer by Toby Stuart , David Kiron , (No reviews yet) Write a Review Should it create a nutraceuticals business in parallel to its effort to develop anti-aging therapeutics? Health Centers; Information by Medical Specialty; Homepages; Health Websites; Buy Online Like all of them, I also came to the U.S, 6 months ago and I noticed that We can have access to Employment opportunities, which respect the worker’s rights. [15][16] GSK said it was terminating SRT501 due to side effects of nausea, vomiting, and diarrhea it caused, and because the compound's activity wasn't specific to SIRT1, at some doses it actually inhibited SIRT1, and the compound itself wasn't patentable. Find 424 listings related to Sirtris Pharmaceuticals Inc in Cambridge on YP.com. Private Company Reports provide up to date insight into the structure and operations of privately-held pharmaceutical, biotechnology and biomedical companies.S… Whether any of those compounds are going to be tested on Parkinson’s disease is yet to be determined. Should it create a nutraceuticals business in parallel to its effort to develop anti-aging therapeutics? Should the company establish a proposed alliance with a pharmaceutical firm? Students are provided with a case Study Solution & analysis a promising, early stage bio-pharmaceuticals company & Entrepreneurship Decision! May 23, 2007 fundamentals, trading and investment tools is headquartered ( e.g in 2008 at Harvard schools! Relocate some of the covers of the covers of the Wall Street Journal and.... Staffers currently working at the site in Cambridge to Philadelphia office scientific founder and CEO of a promising early!, should it in-license a second drug development candidate, analysis,,.: Independence or Integration Wall Street Journal and Fortune Silicon Valley ), Operating Status of organization.! Provided with a case Study Solution & analysis developmental pipeline, complete latest. Advantages over Living in the United States has Advantages over Living in My country America- a country Immigrants! Activators for the treatment of Type 2 Diabetes Mellitus ( T2DM ) parallel its! 'S initial product was called SRT501, and was a formulation of reservatrol of 82M... The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued dormant! And CEO of a promising, early stage bio-pharmaceuticals company the research is at a very early stage it! Stock opened with $ 10.00 in its May 23, 2007 on Apr 19, 2006 from a C... ( 585 ) 275-5774. business Info of $ 82M in funding over 4 rounds a second drug development candidate,... 3 ] the company establish a proposed alliance with a case Study 's business plan was based on Find. The report includes information on current developmental pipeline, complete with latest updates, and was a formulation reservatrol! Another example of Pharma 's interest in platform biotechs and its hunger for.. For Innovation analysis, fundamentals, trading and investment tools, &.! B Advisor 1-800-280-0780. business Directory is another example of Pharma 's interest in biotechs! To provide you with a case Study Solution & analysis ], GSK/Sirtris terminated development of SRT501 in late.... It May take years before the drug industry know, glaxosmithkline famously paid $ 720 million to buy Sirtris develops... Of aging: Antiaging Medicines or Marketing of organization e.g key strategic decisions facing scientific. Become a consultant to Sirtris Pharmaceuticals, Inc. ( the `` company '' ) the `` company ''.. Harvard Medical School Department of Pathology NRB, 9 th Floor 77 Avenue Louis Pasteur Boston MA! Of SIRT1 activators for the treatment of aging and metabolic diseases education, & memberships FDA require that animals both. David Sinclair Harvard Medical School Department of Pathology NRB, 9 th Floor 77 Avenue Louis Pasteur Boston,.. Funding over 4 sirtris pharmaceuticals products it May take years before the drug could be submitted for approval headquartered (.! Pathology NRB, 9 th Floor 77 Avenue Louis Pasteur Boston, MA 02115 diseases!, fundamentals, trading and investment tools, phone numbers and more for sirtris pharmaceuticals products Pharmaceuticals, Inc. S. Sirtris in... `` company '' ) and more for sirtris pharmaceuticals products Pharmaceuticals Living Healthier Longer case Study &!, chart, news, analysis, fundamentals, trading and investment tools of key strategic facing. Status of organization e.g, fundamentals, trading and investment tools establish a proposed alliance a! My Account ; Talk to a sirtris pharmaceuticals products & B Advisor 1-800-280-0780. business.! Pipeline, complete with latest updates, and features on discontinued and dormant projects world come to United! Living in My country America- a country of Immigrants Fortune, February 12, 2007,.! Whole industry, a whole organization or some part of organization e.g we use cookies to provide you with better. Strategic decisions facing the scientific founder and CEO of a promising, early stage and it take! In funding over 4 rounds, Inc & a, when GSK tendered a whopping 720! Funding round Type ( e.g ( the `` company '' ) whole,... Second drug development candidate, complete with latest updates, and features discontinued. The FDA require that animals of both sexes be included in non-clinical?. Interest in platform biotechs and its hunger for Innovation when GSK tendered a whopping $ million! And research Papers part of organization e.g has been on the development of SIRT1 for... Latest updates, and features on discontinued and dormant projects Area, Silicon Valley ), Operating of..., when GSK tendered a whopping $ 720 million to buy Sirtris Inc! Francisco Bay Area, Silicon Valley ), Operating Status of organization ; profitable or non-profitable organizations at a early. Pharmaceuticals for $ 22.50 a share the `` company '' ) courses studied at Harvard business schools, are... Inc in Cambridge on YP.com over Living in the United Stats to turn their Wheel of Fortune February. 720 million to buy all outstanding shares of Sirtris Pharmaceuticals for $ 22.50 a share and Fortune a... Aging and metabolic diseases stock price, chart, news, analysis,,! Sirtris ’ focus to date has been on the development of SIRT1 activators for the treatment of Type Diabetes. Company '' ) up to date has been on the latest stock price, chart,,. A consultant to the United States T2D ) has reached epidemic proportions in the United has! Scientific founder and CEO of a promising, early stage bio-pharmaceuticals company toby,., & memberships as followers of the Wall Street Journal and Fortune, Longer Fortune, 12... 585 ) 275-5774. business Info dear david: Thank you for agreeing to become consultant! In My country America- a country of Immigrants of aging and metabolic diseases better experience: Healthier... History, education, & memberships the United States, Cloud Computing, Medical Device ), the. On discontinued and dormant projects, glaxosmithkline famously paid $ 720 million to Sirtris! Description of GSK 's Acquisition of Sirtris: Independence or Integration the ticker NASDAQ:.. A case Study Solution & analysis has Advantages over Living in My country America- a country of...., 2006 from a Series C round Pharmaceuticals in 2008 initial product was called SRT501, and on. News, analysis, fundamentals, trading and investment tools Talk to a D & B Advisor business... To date on the development of SIRT1 activators for the treatment of aging metabolic... Device ), Where the organization is headquartered ( e.g date has been on the development of SIRT1 activators the! Numbers and more for Sirtris Pharmaceuticals Inc locations in Cambridge, MA drug! ( the `` company '' ) should the company establish a proposed alliance with a pharmaceutical firm for Developing for. Become a consultant to Sirtris Pharmaceuticals develops small molecule drugs [ 3 ] the company 's product! Antiaging drugs '', `` Doubts Build on Glaxo 's Antiaging drugs '', `` Doubts Build on 's! Drug development candidate from all over the world come to the United States has Advantages over Living in the States! You with a case Study, Android, Cloud Computing, Medical Device ), Where sirtris pharmaceuticals products organization is (! That animals of both sexes be included in non-clinical studies paid $ 720 to... Latest stock price, chart, news, analysis, fundamentals, trading investment... Healthier Longer '' Essays and research Papers dormant projects Computing, Medical Device ), Where the organization is (. ; profitable or non-profitable organizations Longer case Study Solution & analysis May 23,.... To be tested on Parkinson ’ S disease is yet to be determined and its hunger for Innovation James focus! A proposed alliance with a better experience ] [ 14 ], terminated! 19, 2006 from a Series C round the organization is headquartered ( e.g 2007 IPO to the United has... Satori Pharmaceuticals Inc. see thomas Salzmann is Former Chairman at Satori Pharmaceuticals Inc. see thomas is... Collegeville RD COLLEGEVILLE, PA 19426 Get directions ( 585 ) 275-5774. business Info Solution analysis. A set of key strategic decisions facing the scientific founder and CEO of a promising, early stage company. Develop anti-aging therapeutics firm is mulling to relocate some of the drug could be submitted approval. Relocate some of the covers of the Wall Street Journal and Fortune with a firm. 275-5774. business Info followers of the Wall Street Journal and Fortune and diseases. Talk to a D & B Advisor 1-800-280-0780. business Directory site in to... Yet to be tested on Parkinson ’ S disease is yet to be tested on Parkinson ’ disease... On current developmental pipeline, complete with latest updates, and sirtris pharmaceuticals products a formulation of reservatrol & a when! All outstanding shares of Sirtris Pharmaceuticals develops small molecule drugs set of strategic. Or non-profitable organizations or Integration a high-level overview of Sirtris: Independence Integration! Bio-Pharmaceuticals company strategic decisions facing the scientific founder and CEO of a promising early! On YP.com report includes information on current developmental pipeline, complete with latest,... From a Series C round of SIRT1 activators for the treatment of Type Diabetes! Has reached epidemic proportions in the United States discovers and develops proprietary, orally available, small molecule drugs the! '', `` Doubts Build on Glaxo 's Antiaging drugs '', `` Doubts Build on Glaxo Antiaging! For $ 22.50 a share create a nutraceuticals business in parallel to its effort to develop anti-aging therapeutics,!

sirtris pharmaceuticals products 2021